Bristol-Myers Squibb has been touted as a potential takeover target in the pharma industry – and potential buyers may take note of the continued strong performance of its cancer drug Opdivo
Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.
Bristol-Myers Squibb has scored a victory against arch-rivals Merck, with a new much more convenient dosing schedule for Opdivo which could help it keep ahead in the sales race.